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Abstract
Delta opioid receptors are implicated in a variety of psychiatric and neurological disorders. These
receptors play a key role in the reinforcing properties of drugs of abuse, and polymorphisms in
OPRD1 (the gene encoding delta opioid receptors) are associated with drug addiction. Delta
opioid receptors are also involved in protecting neurons against hypoxic and ischemic stress. Here,
we first examined a large sample of 738 elderly participants with neuroimaging and genetic data
from the Alzheimer’s Disease Neuroimaging Initiative. We hypothesized that common variants in
OPRD1 would be associated with differences in brain structure, particularly in regions relevant to
addictive and neurodegenerative disorders. One very common variant (rs678849) predicted
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differences in regional brain volumes. We replicated the association of this single-nucleotide
polymorphism with regional tissue volumes in a large sample of young participants in the
Queensland Twin Imaging study. Although the same allele was associated with reduced volumes
in both cohorts, the brain regions affected differed between the two samples. In healthy elderly,
exploratory analyses suggested that the genotype associated with reduced brain volumes in both
cohorts may also predict cerebrospinal fluid levels of neurodegenerative biomarkers, but this
requires confirmation. If opiate receptor genetic variants are related to individual differences in
brain structure, genotyping of these variants may be helpful when designing clinical trials
targeting delta opioid receptors to treat neurological disorders.
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INTRODUCTION
Endogenous opioid peptides are part of the neurohormonal system. They function as
hormones, secreted into the blood, and delivered to several distant target tissues. They also
act as neuromodulators, influencing how other transmitters act in the central nervous system
[Janecka et al., 2004]. Opioid receptors have four major subtypes: mu, delta, kappa, and
nociceptin. These G protein-coupled receptors are encoded by four distinct genes and are
stimulated by various endogenous opioid peptides, as well as by opiate drugs.
Opioids may mediate reward by disinhibiting dopamine neurons in the ventral tegmental
area, resulting in increased dopamine release in the nucleus accumbens [Volkow et al.,
2011]. Mu opioid receptors are primary modulators of the rewarding effects of drugs of
abuse [Volkow et al., 2011]. Over the last decade, many animal studies have implicated
delta opioid receptors in reward [Hirose et al., 2005], opioid tolerance [Zhang et al., 2006]
and dependence [Wu et al., 2011], and in several aspects of ethanol addiction, including
heavy consumption [Nielsen et al., 2012] and escalation of intake contributing to abuse
[Barson et al., 2010]. Chronic ethanol exposure changes delta opioid receptor expression
[Van Rijn et al., 2012a], and pharmacological manipulations of these receptors modulate
ethanol-related behaviors such as place preference [Van Rijn et al., 2012b] and withdrawal-
induced anxiety [Van Rijn et al., 2010]. In addition, several single-nucleotide
polymorphisms (SNPs) in the OPRD1 gene, which encodes delta receptors, contribute to the
risk for substance abuse disorders [Levran et al., 2012].
Delta receptors are also involved in neurodegeneration. They promote the processing of
amyloid beta (Aβ) precursor protein. Knockdown or antagonization of delta receptors
ameliorates Aβ-related pathology and Aβ-dependent behavioral deficits in mice [Teng et al.,
2010]. One OPRD1 polymorphism (rs1042114) is strongly associated with opioid
dependence [Zhang et al., 2008], and changes the evolutionarily conserved phenylalanine to
cysteine in the N-terminus of the receptor. In human cell lines, this change in the amino acid
sequence of the delta receptors leads to a detrimental accumulation of one type of Aβ
precursor protein, which is degraded less efficiently [Sarajarvi et al., 2011]. Thus, the G
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allele, which confers a predisposition to addiction [Zhang et al., 2008], also seems to
promote neurodegeneration [Sarajarvi et al., 2011].
Commonly carried variants in the OPRD1 gene have been associated with a variety of
psychiatric and neurological phenotypes, but to our knowledge, no investigation has
assessed whether they influence brain structure. Here, we hypothesized that common
variants in OPRD1 might be associated with structural differences in limbic circuits relevant
to addiction and in frontotemporal regions vulnerable to neurodegeneration. We tested this
hypothesis in a large sample of elderly subjects; to test the generalizability of the finding, we
also assessed a replication sample of young adult twins, greatly reducing the risk of false
positive findings.
After discovering that the rs678849 locus was associated with local brain volumes in various
regions, we performed exploratory tests in the elderly cohort, to assess its effects on other
neurodegenerative markers in the cerebrospinal fluid (CSF). We hypothesized that the C
allele, which was associated with smaller regional brain volumes, might also be associated
with CSF markers of neurodegeneration, including measures of amyloid and tau proteins
that abnormally accumulate in Alzheimer’s disease.
METHODS
Subjects
We analyzed two independent samples with neuroimaging and genetic data: the Alzheimer’s
Disease Neuroimaging Initiative (ADNI) and the Queensland Twin Imaging (QTIM) study.
ADNI participants were recruited from 58 sites across North America. The study was
conducted according to the Good Clinical Practice guidelines, the Declaration of Helsinki,
and U.S. 21 CFR Part 50 (Protection of Human Subjects), and Part 56 (Institutional Review
Boards). Written informed consent was obtained from all participants before protocol-
specific procedures were performed. All ADNI data are publicly available (at http://
www.loni.ucla.edu/ADNI/). To avoid the known effects of population stratification on
genetic analysis [Lander and Schork, 1994], we only included non-Hispanic Caucasian
subjects identified by self-report and confirmed by multidimensional scaling analysis [Stein
et al., 2010]. The ADNI cohort included multiple diagnostic groups: patients with
Alzheimer’s disease (AD), subjects with mild cognitive impairment (MCI), and healthy
elderly (cognitively normal) participants. We used the full ADNI sample, including data
from all diagnostic groups, due to the very limited power available when performing any
genetic association analysis. Typical effects of candidate genes on the phenotype are often
around 1% of the mean value per allele [Stein et al., 2012] so we often pick up effects only
when ADNI’s full sample is included. Effect sizes for individual genetic variants on brain
structure in particular are expected to be small, so the neuroimaging genetics analysis would
be underpowered if we further subdivided the sample. Our final analysis comprised 738
individuals (average age ± s.d. = 75.52 ± 6.78 years; 438 men/300 women) 178 AD, 354
MCI, and 206 healthy participants (Table I).
The QTIM sample has been described in detail elsewhere [Blokland et al., 2011; De
Zubicaray et al., 2008; Wright and Martin, 2004]. Briefly, the QTIM study is a large 5-year
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Australian research project to examine genetic effects on brain structure and function.
Subjects consist of healthy, young adult monozygotic (MZ) and dizygotic (DZ) twins and
their singleton siblings. All twins were screened to exclude pathology known to affect brain
structure. No twins reported a history of significant head injury, neurological or psychiatric
illness, substance abuse or dependence, or had a first-degree relative with a psychiatric
disorder. The cohort is predominantly Caucasian; 10 individuals were excluded as ancestry
outliers, identified by principal component analysis of genome-wide SNP data (outliers were
at least six standard deviations from the mean along the first two principal component axes).
Written informed consent was obtained from all subjects before performing protocol-
specific procedures. Our final analysis included 578 individuals; age 23.80 ± 2.24 years,
including 224 men and 354 women (Table II).
Genotyping and SNP Selection
Both the ADNI and QTIM samples were genotyped using the Illumina 610-Quad BeadChip
(San Diego, CA). Using the Tagger algorithm in Haploview [v4.2; Barrett et al., 2005], tag
SNPs were selected to provide coverage of the OPRD1 gene (Fig. 1). These five SNPs
spanning OPRD1 were analyzed for association with brain volumes in ADNI. Only the top
SNP hit (at the rs678849 locus) was subsequently analyzed for association with CSF
biomarkers in a subset of ADNI participants (who volunteered for CSF assessments) and
analyzed for association with brain volumes in the QTIM sample for replication purposes.
Image Acquisition, Correction and Preprocessing
ADNI subjects were scanned with a standardized MRI protocol developed for this cohort
[Jack et al., 2008; Leow et al., 2006]. Briefly, high-resolution structural brain MRI scans
were acquired at 58 sites using 1.5 T MRI scanners. A sagittal 3D MP-RAGE sequence was
used, optimized for consistency across sites [Jack et al., 2008; time of repetition (TR)/time
of echo (TE) = 2400/1000 ms; flip angle = 8°; field of view = 24 cm; final reconstructed
voxel resolution = 0.9375 mm × 0.9375 mm × 1.2 mm]. Image corrections were applied
using a processing pipeline at the Mayo Clinic, consisting of: (1) a procedure termed
GradWarp to correct geometric distortion due to gradient nonlinearity [Jovicich et al.,
2006], (2) a “B1-correction”, to adjust for image intensity inhomogeneity due to B1
nonuniformity using calibration scans [Jack et al., 2008], (3) “N3” bias field correction, for
reducing residual intensity inhomogeneity [Sled et al., 1998], and (4) geometrical scaling,
according to a phantom scan acquired for each subject [Jack et al., 2008], to adjust for
scanner- and session-specific calibration errors. To adjust for global differences in brain
positioning and scale, all subjects’ scans were linearly registered to the stereotaxic space
defined by the International Consortium for Brain Mapping [ICBM-53; Mazziotta et al.,
2001] using a 9-parameter (9P) transformation [three translations, three rotations, three
scales; Collins et al., 1994]. For ADNI, we used standard trilinear interpolation and
resampled the resulting aligned scans to have 1 mm isotropic voxels.
In the QTIM cohort, all subjects were imaged on the same scanner using structural whole
brain MRI at 4 T (Bruker Medspec). T1-weighted images were acquired with an inversion
recovery rapid gradient echo sequence (inversion time/TR/TE = 700/1, 500/3.35 ms; flip
angle = 8°; slice thickness = 0.9 mm, with a 256 × 256 acquisition matrix). All images were
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initially corrected for intensity nonuniformity [Sled et al., 1998] within an automatically
delineated mask of the brain [Smith, 2002]. Images were then spatially normalized to the
ICBM-152 template [Mazziotta et al., 2001] using a 9P transformation that rotated and
scaled each image to minimize a normalized mutual information cost function [Jenkinson et
al., 2002]. For the QTIM cohort, we did not use standard trilinear interpolation. Instead,
images were then resampled in the space of the template using sinc interpolation to yield 1
mm3 iso-tropic voxels. In this way, each brain was globally matched in size and mutually
aligned, but local differences in shape and size remained intact. Subjects’ brain images were
not skull-stripped during preprocessing for either cohort.
Minimal Deformation Target and Tensor-Based Morphometry
For each cohort, we created a minimal deformation target (MDT), which serves as an
unbiased average template image for automated image registration, and to reduce statistical
bias. For the ADNI sample, an MDT was created from the MRI scans of 40 randomly
selected healthy elderly subjects, as detailed elsewhere [Hua et al., 2008a, 2008b]. For the
QTIM cohort, an MDT was created from the T1-weighted images of 40 (20 female/20 male)
randomly selected, nonrelated participants [Gutman et al., 2010]. The MDT image was
calculated from a geometric composite averaging of source moves from the sKLMI to an
average affine-registered target image following the procedure detailed elsewhere [Hua et
al., 2008a, 2008b].
To quantify 3D patterns of volumetric tissue variations, all individual T1-weighted images
(N = 1,316) were nonlinearly aligned to their cohort-specific template with an inverse-
consistent 3D elastic warping technique using a mutual information cost function [Leow et
al., 2005]. For each subject, a separate Jacobian matrix field was derived from the gradients
of the deformation field that aligned that individual brain to the MDT template. The
determinant of the local Jacobian matrix was derived from the forward deformation field to
characterize local volume differences. Color-coded Jacobian determinants were used to
illustrate regions of volume expansion, that is, those with det J(r) > 1, or contraction, that is,
det J(r) < 1 [Chung et al., 2001; Freeborough and Fox, 1998; Riddle et al., 2004; Thompson
et al., 2000] relative to the group template. As all images within each cohort were registered
to the same study-specific template, these Jacobian maps shared common anatomical
coordinates, defined by the normal template. Individual Jacobian maps were retained for
further statistical analyses.
Regression of Structural Brain Differences with the Tag SNPs
In the ADNI cohort, we investigated the effects of five tag SNPs on local brain volumes. For
each SNP, we used univariate linear regression to associate the number of minor alleles (0,
1, or 2) with the Jacobian values (describing the amount of brain tissue deficit or excess
relative to the standard template) at each voxel in the brain, after covarying for age and sex.
In the QTIM cohort, kinship structure was also taken into account using mixed-effects
modeling. We performed univariate associations with the top SNP hit identified in ADNI
(rs678849), using a mixed model approach controlling for age and sex [emmaX: http://
genetics.cs.ucla.edu/emmax/news.html; Kang et al., 2010], to account for the familial
relatedness between subjects. A kinship matrix was used to describe the expected proportion
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of common genetic variation between subjects. As detailed elsewhere [Jahanshad et al.,
2012], a “0” in the kinship matrix represents the relation between unrelated individuals, “1”
denotes the relationship of a pair of MZ twins (with identical genomes), and DZ twins and
nontwin siblings within the same family are denoted by “0.5” (as they are expected to share
approximately half of their SNPs).
Multiple Comparisons Correction
Computing thousands of association tests across the brain can introduce a high Type I (false
positive) error rate in neuroimaging studies, if not controlled. To control these errors, we
used a searchlight method for false discovery rate (FDR) correction [Langers et al., 2007]
which controls the FDR, where possible, in any reported statistical maps. We implemented
this searchlight method to correct the map of statistical associations between the image
phenotype (morphometry) and genotype at the rs678849 locus. All maps shown are
thresholded at the appropriate corrected P-value, after performing searchlight FDR (q =
0.05), to show only regions of significance that passed the multiple comparisons correction.
Post Hoc Analyses: CSF Biomarkers in ADNI
For 387 of our subjects (75.07 ± 7.0 years, 223 men, and 164 women), CSF data was
available from the ADNI public database (www.loni.ucla.edu/ADNI/Data/). Baseline values
of two CSF biomarkers of neurodegeneration (total ttau and the beta amyloid isoform,
Aβ42) were analyzed. CSF samples were obtained through lumbar puncture, after an
overnight fast. Samples from various sites were transferred, on dry ice, to the ADNI
Biomarker Core Laboratory at the University of Pennsylvania Medical Center, where the
levels of t-tau and Aβ42 are measured with a multiplex immunoassay platform under the
direction of Drs. Leslie Shaw and John Trojanowski [Trojanowski et al., 2010].
We first tested the rs678849 polymorphism for association with CSF biomarker levels using
an additive model, and the results failed to reach statistical significance. In ADNI, CSF is
available for only around half the subjects who underwent neuroimaging, which makes it
more difficult to detect the effects of a single SNP in a three-group analysis. As so few
subjects were included in the CSF analyses, we also tested a dominant model. We compared
mean biomarker levels between C homozygotes and carriers of 1 or 2 T alleles. We used
multiple regression to test how well the genotype at the rs678849 locus might predict CSF
biomarker levels, after adjusting for age and sex.
RESULTS
Neuroimaging
In the ADNI sample, one very common variant, the intronic OPRD1 polymorphism
rs678849 (C/T, minor allele frequency: T = 0.462), predicted differences in regional brain
volumes, after covarying for age and sex. Smaller volumes in frontal (anterior cingulate
gyrus, right middle frontal and precentral gyrus, left inferior frontal gyrus, and frontal pole),
temporal (inferior and middle temporal gyri, and temporal fusiform gyri, especially on the
left) and occipital brain regions (lateral occipital and occipital fusiform gyri) were
statistically related to carrying at least one C allele (Fig. 2, critical P = 7.74 × 10−5). None of
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the other four tag SNPs (rs2236856, rs499062, rs508448, and rs4654327) was significantly
associated with regional brain volumes, after multiple comparisons correction.
The top SNP hit (at the rs678849 locus) also predicted differences in regional brain volumes
in the QTIM cohort, after covarying for age and sex and after multiple comparisons
correction. Smaller volumes in the orbitofrontal cortex, in superior and posterior parietal
regions, and in the right cerebellum were statistically related to carrying at least one C allele
(Fig. 3). On all significance maps, the color bar encodes the average percentage of volume
difference relative to the template for the subjects carrying at least one C allele, versus
noncarriers (Figs. 2 and 3).
Post Hoc Analyses
In 387 of our ADNI subjects, CSF biomarkers of neurodegeneration (total t-tau and the beta
amyloid isoform Aβ42) were obtained. Based on our finding that the rs678849 predicted
differences in regional brain volumes, we tested how well genotype at the rs678849 locus
predicted CSF measures of t-tau and Aβ42, adjusting for age and sex. These post hoc
analyses revealed trends (0.05 < P < 0.10) for a main effect of genotype on CSF levels of
biomarkers associated with neurodegeneration (P = 0.079 for t-tau/Aβ42 ratio, P = 0.066 for
t-tau levels), and trend level evidence for a possible genotype by diagnosis interaction (P =
0.096 for t-tau/Aβ42 ratio, P 0.077 for t-tau), with AD coded as “2”, MCI coded as “1”, and
healthy elderly coded as “0”.
We performed further exploratory tests to examine results within diagnostic groups, to
determine if any one diagnostic group was responsible for carrying the effect. Genotype
predicted levels of neurodegenerative biomarkers in the CSF for healthy elderly (n = 105)
but not for individuals with MCI (n = 182) or AD (n = 100). Healthy homozygous C allele
carriers had higher t-tau/Aβ42 ratios (suggesting a greater risk for neurodegenerative
diseases) than participants with at least one T-allele (P = 0.027, Fig. 4). In addition, healthy
homozygous C allele carriers showed a trend for higher mean t-tau levels (perhaps
suggesting a higher risk for neurodegenerative disorders) than participants with at least one
T-allele (P = 0.063, Fig. 5).
DISCUSSION
This study is the first to report an association between brain structure and a commonly
carried opioid receptor genetic variant. We identified a SNP in OPRD1, the gene encoding
delta opioid receptors, which predicts tissue volumes in various brain regions. In much
previous research, investigating gene–brain relationships, replication of initially promising
results has proven very difficult. For instance, our group recently found that several
candidate genes reportedly related to hippocampal volumes (including BDNF, DISC1, and
COMT) were not significantly associated with hippocampal volumes in genome-wide
association meta-analyses from a large multinational consortium [Stein et al., 2012]. Here,
we were able to replicate the genetic association of the C-allele at the rs678849 locus with
smaller regional brain volumes in samples from two continents (United States and
Australia), separated in mean age by ~50 years, and using data collected on scanners with
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different field strengths (1.5 vs. 4 T), suggesting that the association of this OPRD1 SNP
with brain volumes may be robust and persist throughout life.
Although the same allele was associated with reduced tissue volumes in both samples, none
of the significant voxels after correction for multiple comparisons in the QTIM sample
overlapped with the voxels that survived statistical thresholding in the original ADNI
sample. In the QTIM sample, we performed an unbiased search across each voxel of the full
brain without incorporating previous information from our earlier tests in the ADNI dataset.
The reason for this is that voxels that are significant after correction for multiple
comparisons do not necessarily represent the only voxels where this OPRD1 SNP may have
an effect. We wanted to perform an analysis that allowed for the possibility to observe an
effect anywhere in the brain. As such, the most appropriate test is a brain-wide search, as it
asserts only that the gene has some effect in the brain, rather than making a stronger
assertion about its specific localization.
From a biological point of view, subjects in the QTIM study are, on average, around 50
years younger than ADNI participants. Thus, a gene may have regional effects on the brain
that either spread out or become more regionally specific over the human lifespan. Or,
perhaps more likely, it could be that a very weak effect is spread over the entire brain in both
samples, but due to noise and biological variability in the two cohorts, different locations in
the brain provide the highest effect sizes to the statistical maps in each cohort, with the result
that the maps are significant in aggregate. As an alternative more stringent approach, a
conjunction test [Jovicich et al., 2006] could be performed to directly identify voxels where
a gene effect is statistically significant in several cohorts at once. Such tests have relatively
low power, as they require that the gene effect be found consistently in the same voxels in
all cohorts, rather than across the brain in aggregate in each cohort. Different formulations
of the null hypothesis may therefore greatly affect the power and scope of the inferences. In
addition, there may be gene effects that are detectable at only one part of the lifespan, so
many biologically important gene effects may not be detectable in both young and old
cohorts.
The association of this OPRD1 SNP with tissue volumes in both samples is an important
finding for several reasons. Degenerative disorders are typically diagnosed only after severe
brain changes have occurred, so it is vital to discover genetic variants that may influence
brain volumetry or atrophy in the general population. Animal and human cell line studies
implicate delta receptors in neurodegeneration and neuroprotection [Feng et al., 2009],
strengthening the case that these receptors may affect brain structure at the macroscopic
level. For the first time, we show a direct association between a variant in the gene encoding
delta receptors and regional brain volumes, in several systems where cellular and molecular
processes are mediated by these receptors.
The genotype associated with reduced volumes (the C allele at the rs678849 locus) also
predicted CSF levels of classical neurodegenerative biomarkers in healthy elderly people,
suggesting a possible link to physiological measures of neurodegenerative diseases. This
association was only significant in healthy elderly, perhaps because, in the MCI and AD
subjects, other genes such as ApoE [Schellenberg and Montine, 2012] may be a primary
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driver factor affecting CSF levels of neurodegenerative biomarkers. We were unable to
replicate these results due to the lack of comparable data from a different cohort. In addition,
one could argue that some multiple comparisons correction would be appropriate, as two
biomarkers were assessed. Although a Bonferroni correction may be overly conservative as
the total tau and t-tau/Aβ42 ratio are correlated measures, this would increase the P-values
well above the trend range of significance. These limitations make the CSF findings less
convincing than the imaging results. Nevertheless, if replicated, this SNP, in conjunction
with others [Kohannim et al., 2012], may eventually help predict who among the
asymptomatic elderly may be at greater risk for developing neurodegenerative disorders.
Such a genetic profile may help to target interventions to those with greater inherited
predisposition for such diseases.
Interestingly, an association between rs678849 and cocaine addiction was reported in a
recent study [Crist et al., 2012]. The authors found that the T allele was overrepresented in
the nonaddicted control population, suggesting a “protective” effect. Therefore, similar to
the rs1042114 G allele which is associated both with opiate addiction [Zhang et al., 2008]
and with a detrimental accumulation of Aβ precursor protein [Sarajarvi et al., 2011], the C
allele at the rs678849 locus appears to confer a predisposition to not only cocaine addiction,
but also to higher CSF levels of neurodegenerative biomarkers and smaller regional brain
volumes. We cannot exclude the possibility that individuals genetically predisposed to
cocaine addiction and other risky behaviors or addictive substances, may show brain
changes due to downstream effects of their lifestyle choices, rather than as a direct influence
of a specific SNP. This may be an alternative explanation for the different brain structure
effects in the elderly cohort. Even so, we observed volumetric differences in young and
healthy subjects screened to exclude neurological or psychiatric illnesses and substance
abuse or dependence, so the structural brain differences may be directly associated with their
genotype.
Interestingly, in the QTIM sample, we observed a statistical association between the C allele
at this locus and lower volumes in superior and posterior parietal cortices, and in the
orbitofrontal cortex, all of which have been implicated in studies of drug abuse. Reduced
superior parietal volumes were associated with alcohol use disorders [Van Holst et al., 2012]
and stimulant abuse was linked to abnormal functional activation in posterior parietal
regions [Aron and Paulus, 2007]. Volume reductions in the orbitofrontal cortex are reported
in drug abusers [Tanabe et al., 2009], who also show functional and metabolic abnormalities
in this region [London et al., 2000]. A single DNA variant may be associated with diverse
phenotypes (pleiotropy), so future studies are needed to determine whether the rs678849
polymorphism confers a higher risk for addiction and neurodegeneration via overlapping or
different biological mechanisms.
We identified a polymorphism in OPRD1 associated with regional brain volumes, but we
are not able to provide mechanistic evidence for how this SNP might affect brain structure.
Unlike the rs1042114 SNP, which leads to an amino acid substitution affecting the
functioning of delta receptors, rs678849 is an intronic SNP that is less coherently linked
with clear changes in function. The mechanisms that relate this polymorphism to brain
volumes, levels of neurodegeneration markers, and addiction in other studies remain largely
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unknown. SNPs in noncoding regions can affect gene splicing, transcription factor binding,
mRNA degradation, and other molecular genetic processes. We cannot conclude with
certainty that the rs678849 SNP is driving the observed association with brain volumes.
Untyped variants with high linkage disequilibrium to this SNP may be responsible for the
signal.
Delta opioid receptors are an evolving target for the treatment of many neurological and
psychiatric diseases [Pradhan et al., 2011]. The genetic association of an OPRD1 variant
with neuroimaging and biomarker phenotypes, along with the known involvement of the
OPRD1 gene in drug abuse, provide additional support for the relevance of these receptors
as possible therapeutic targets in both neurodegenerative and addictive disorders. Although
neuroimaging changes are not the primary outcome measure of most drug trials, genotyping
of the rs678849 variant may be of interest in drug trials targeting delta receptors to treat
brain disorders, as patients could, in principle, have therapeutic outcomes that depend on
their genotype. Clearly, greater understanding of how OPRD1 and other genes affect the
brain is necessary before we can contemplate clinical trials using it as a pertinent genotype.
Nevertheless, this study may eventually inform novel and targeted pharmacological
interventions for preventing and managing neurological disorders.
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Figure 1.
Pattern of linkage disequilibrium (LD) across all OPRD1 SNPs and location of tag SNPs
among other OPRD1 SNPs genotyped in the HapMap European (CEU) sample. The pattern
of LD across all OPRD1 SNPs genotyped in the HapMap sample is illustrated here. The
SNPs are shown on a scale representing their position on chromosome 1. The tag SNPs
selected with Haploview (v4.2) are highlighted in yellow. This image is modified from the
HapMap website (http://www.hapmap.org/). [Color figure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
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Figure 2.
Effects of C allele at the rs678849 locus in the delta opioid receptor gene, on regional brain
volumes in the ADNI cohort. The intronic OPRD1 polymorphism rs678849 was
significantly associated with regional frontal, temporal, and occipital brain volumes.
Negative beta values (warm colors) show regions where C allele carriers had lower tissue
volumes. Tests for associations are adjusted for age and sex; maps are corrected for multiple
comparisons with the searchlight false discovery rate (FDR) method. Images are in
radiological convention (left side of the brain shown on the right). [Color figure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Figure 3.
Effects of C allele at the rs678849 locus in the delta opioid receptor gene, on regional brain
volumes in the QTIM cohort. The same OPRD1 polymorphism, rs678849, was significantly
associated with regional frontal, temporal, and occipital brain volumes. Negative beta values
(warm colors) show regions where C allele carriers had lower tissue volumes. Tests for
associations are adjusted for age and sex; maps are corrected for multiple comparisons with
the searchlight false discovery rate (FDR) method. Images are in radiological convention
(left side of the brain shown on the right). [Color figure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
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Figure 4.
Effects of genotype at the rs678849 locus on t-tau/Aβ42 ratios Significant main effect of
genotype on t-tau/Aβ42 ratios in healthy elderly (n = 105, represented in red). Homozygous
C allele carriers had higher ratios (suggesting a greater risk for neurodegenerative diseases)
than participants with at least one T allele (P = 0.027). AD: Alzheimer’s disease patients
(blue) and MCI: participants with mild cognitive impairment (green). [Color figure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Figure 5.
Effects of genotype at rs678849 locus on mean t-tau levels. Trend for main effect of
genotype on mean t-tau levels in healthy elderly (n = 105, represented in red). Homozygous
C allele carriers had higher mean t-tau levels (suggesting a greater risk for
neurodegenerative diseases) than participants with at least one T allele (P = 0.063). AD:
Alzheimer’s disease patients (blue), MCI: participants with mild cognitive impairment
(green), and t-tau levels are reported in pg/ml. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
Roussotte et al. Page 18
Hum Brain Mapp. Author manuscript; available in PMC 2014 June 05.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Roussotte et al. Page 19
TABLE I
Demographic and genetic data for the ADNI cohort (after restricting the genetic analysis to Caucasians)
ADNI Males Females Total
Total 438 300 738
Healthy elderly 111 95 206 (28%)
MCI 229 125 354 (48%)
AD 98 80 178 (24%)
rs678849 0 C alleles 126 82 208 (28%)
rs678849 1 C alleles 216 157 373 (51%)
rs678849 2 C alleles 96 61 157 (21%)
Mean age (±s.d.) 75.90 (±6.76) 74.98 (±6.78) 75.52 (±6.78)
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TABLE II
Demographic and genetic data in the QTIM cohort
QTIM Males Females Total
Total 224 354 578
rs678849 0 C alleles 55 102 157 (27%)
rs678849 1 C alleles 126 171 297 (51%)
rs678849 2 C alleles 43 81 124 (22%)
Mean age (±s.d.) 23.54 (±2.22) 23.96 (±2.25) 23.80 (±2.24)
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